IL17A and Alzheimer disease: Because AD is an inflammatory disease mediated by cytokines such as IL-4, IL-13, IL-17, and thymic stromal lymphopoietin (TSLP) [10], topical corticosteroids and calcineurin inhibitors are applied as first-line therapy for AD patients in order to reduce inflammation [8].